Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL
Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel, Switzer...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
08 April 2003
|
| In: |
Leukemia
Year: 2003, Volume: 17, Issue: 4, Pages: 691-699 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2402879 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.leu.2402879 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/2402879 
|
| Author Notes: | C.A. Schiffer, R. Hehlmann and R. Larson |
| Summary: | Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel, Switzerland, and formerly STI571) is having a profound effect on the treatment and management of all stages of CML and Philadelphia chromosome positive (Ph+) ALL. New treatment algorithms are being developed. Should imatinib replace or be combined with existing therapies? To address this question, we review the pros and cons of therapy with interferon-α (IFN-α), allogeneic transplantation, autologous transplantation, imatinib, and in the case of Ph+ ALL, chemotherapy and experimental approaches. Conservative and aggressive treatments will be discussed and new molecular methods of monitoring cytogenetic response and their significance will also be reviewed. |
|---|---|
| Item Description: | Gesehen am 12.05.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/sj.leu.2402879 |